JAK2 and myeloproliferative neoplasm: Certain subgroups, notably DP1 and DP5, were distinguished by their unique mutational profiles—JAK2 in DP1 and CALR in DP5—and associated clinical and laboratory features of MPN, which led to a very favorable prognosis.